Immunotherapy and Immune Checkpoints
Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies. Among the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are initiated by ligand–receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunetherapeutics to achieve US Food and Drug Administration (FDA) approval.
- Combinations of Check-Point Inhibitors
- In Vivo Discovery of Immunotherapy Targets
- Immune Suppression and Microenvironment
- Sequencing or Combination Approaches in Immunotherapy
- Chimeric Antigen Receptor Re-Directed T Cell Therapy
Related Conference of Immunotherapy and Immune Checkpoints
5th International conference on Vaccines, Vaccination and Immunization
Immunotherapy and Immune Checkpoints Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibiotics
- Antibiotics used in Industries
- Antibiotics: Advances in Treatment
- Antibiotics: Applications
- Antibiotics: Clinical Trials
- Antibiotics: Infectious Diseases
- Antibiotics: Mechanism of Action
- Antibodies: Infectious Diseases
- Antibodies: Medical Applications
- Antibody Conjugate Therapeutics: Challenge and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Humanization Technologies
- Auto Immune Antibodies
- Bio therapeutics : Early Analytical Development
- Bio Therapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio Therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing(NGS) in Antibody Discovery and Engineering: Overview and Applications
- Protein Engineering and Genetic Engineering
Related Journals
Are you interested in
- Cancer Immunology and Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Cell & Plant Biology - IMMUNOLOGY 2024 (Spain)
- Cell Biology - IMMUNOLOGY 2024 (Spain)
- CELL, ANIMAL & PLANT BIOLOGY - IMMUNOLOGY 2024 (Spain)
- Clinical Immunology & Current & Future Research - IMMUNOLOGY 2024 (Spain)
- Immune System - IMMUNOLOGY 2024 (Spain)
- Immuno informatics & Systems immunology - IMMUNOLOGY 2024 (Spain)
- Immuno-Genetics - IMMUNOLOGY 2024 (Spain)
- Immunogenetics - IMMUNOLOGY 2024 (Spain)
- Immunohistochemistry - IMMUNOLOGY 2024 (Spain)
- Immunology - IMMUNOLOGY 2024 (Spain)
- Immunotherapy - IMMUNOLOGY 2024 (Spain)
- Nutritional Immunology - IMMUNOLOGY 2024 (Spain)
- OncoImmunology - IMMUNOLOGY 2024 (Spain)
- Pediatric and Neonatal Immunology - IMMUNOLOGY 2024 (Spain)
- Reproductive Immunology - IMMUNOLOGY 2024 (Spain)
- Transplantation and Computational Immunology - IMMUNOLOGY 2024 (Spain)
- Vaccines & Immunization - IMMUNOLOGY 2024 (Spain)
- Virology and infectious diseases - IMMUNOLOGY 2024 (Spain)